Novartis Heart-Failure Pill Hits Hurdles With Doctors
Novartis won regulatory approval last summer for a heart-failure pill, Entresto, that it called “one of the most remarkable drugs in cardiovascular medicine in the last several decades.” Since then, it has faced a problem: getting doctors to prescribe it.